MYCN Amplification Predicts Poor Outcomes in Gliomas

Study published in The Journal of Pathology Clinical Research.

Analysed 190 patients with IDH-mutant gliomas.

MYCN amplification found in 14.7 percent of cases.

Amplification linked to shorter survival.

Proposed reclassification of lower-grade gliomas with MYCN amplification as grade 4.

Kaplan–Meier and Cox regression used for survival analysis.

Histological features included eosinophilic cytoplasm and necrosis.